Cardiovascular Risk Left Behind: An Interactive Exploration of Triglyceride-Rich Remnant Lipoproteins

Released On
October 19, 2021

Expires On
October 19, 2022

Media Type

Completion Time
60 minutes

Cardiology, Endocrinology, Pharmacy

Cardiovascular Disease, Pharmacology

Scroll to the Bottom of this Information to Begin this Course

This activity is provided by National Lipid Association.

This educational activity is supported by educational grants from Pfizer.

Credit Available

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)
  • Pharmacists — 1.0 Pharmacy Contact Hours
  • Nurses — 1.0 Nursing Contact Hours

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This curriculum and corresponding interventions are designed for Internists, Primary Care Physicians, Family Medicine, Cardiologists, Endocrinologists, Lipid Specialists, Nurse Practitioners, Advanced Practice Nurses, and/or Physicians Assistants, Pharmacists who are involved in the care and treatment of patients with ASCVD.

Program Overview

Join us for this 1-hour interactive online activity with an in-clinic reference guide aimed at providing clinicians with a comprehensive overview of approaches to residual cardiovascular risk reduction in high-risk patients with maximally controlled LDL-cholesterol. This highly interactive activity contains animations, mock patient charts, and interactivity learning.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Discuss the mechanism and cause of triglyceride-rich remnant lipoproteins.
  • Demonstrate effective cardiovascular risk assessment and shared decision-making with high-risk patients with controlled LDL-cholesterol.
  • Identify in which patients triglyceride-rich lipoproteins may be the primary treatment target.
  • Outline appropriate therapy options for high CVD risk patients with elevated triglyceride levels.
  • Discuss strategies to improve the knowledge, skills or performance of the healthcare team.




Vera A. Bittner, MD, MSPH, FNLA- Chair

Professor of Medicine
Section Head, General Cardiology, Prevention, and Imaging
Medical Director, Cardiac Rehabilitation and CCU
University of Alabama at Birmingham
Birmingham, AL


Seth S. Martin, MD, MHS- Faculty

Associate Professor of Medicine – Cardiology
Director, Advanced Lipid Disorders Clinic
Ciccarone Center for the Prevention of CV Disease
Division of Cardiology, Department of Medicine
The Johns Hopkins University School of Medicine
Baltimore, MD


Michael Miller, MD- Faculty

Professor of Cardiovascular Medicine, Epidemiology & Public Health
University of Maryland School of Medicine
Director, Center for Preventive Cardiology
University of Maryland Medical Center
Baltimore, MD


Physician Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by The National Lipid Association and Vindico Medical Education. The National Lipid Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


Credit Designation

Physician Credit Designation Statement

The National Lipid Association designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in this activity.

Physician Assistants

NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME.

Pharmacist Accreditation Statement

Universal Activity Number – JA0007192-0000-21-034-H01-P (Application)
This Activity has been approved for 1.0 contact hour(s) (.10 CEUs) of the Accreditation Council for Pharmacy Education.



The maximum number of hours awarded for this CE activity is 1.0 contact hours.
For the advanced practice nurse, this activity has 0.25 contact hours of pharmacotherapy content.

Disclosures of Conflicts of Interest

Vera A. Bittner, MD, MSPH, FNLA

  • Advisory Board: Sanofi
  • Advisory Committee: Pfizer
  • Contracted ResearchX: Amgen, AstraZeneca, DalCor, Esperion, Novartis, Sanofi


Seth Martin, MD, MHS

  • Consultant: Amgen, AstraZeneca, Sanofi, 89Bio


Michael Miller, MD

  • Consultant: Amarin, Pfizer, 89Bio


Susan Halli Demter, DNP, FNP-BC, CLS, FNLA- Peer Reviwer has nothing to disclose.

NLA Staff has nothing to disclose.

Instructions for Participation and Credit

There are no fees for participating and statements of credit will be awarded based on the participant’s completion of the following elements: read the introductory CE material, complete all of the modules, and complete the evaluation, and post-test, answering at least 70% of the post-test questions correctly. Partial credit may be awarded for ACPE credit. A statement of credit will be available upon completion of an online evaluation/claimed credit form. The deadline to claim credit is October 31, 2022.

*IMPORTANT* Pharmacists MUST request credit before October 31, 2022. Credit requested after this date will be subject to a fee by the accreditation board.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

Disclosure of Unlabeled Use

The National Lipid Association requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.


This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

Contact Information

For CME questions please contact: